Oncotarget · 2019 · 16 citations · 28 references
MedicineOncologyPharmacologyEndocrine OncologyMedical OncologyMolecular OncologyNeuroendocrine Tumor TherapyOncogenic VirusesOncolytic Virus TherapyNeuroendocrine Tumor PharmacologyOncolytic Viral TherapyOncolytic Viral VectorsTumor Cell Proliferation
// Hideyuki Matsushima 1 , Masaki Kaibori 1 , Masahiko Hatta 1 , Morihiko Ishizaki 1 , Richi Nakatake 1 , Tadayoshi Okumura 1 , 2 , Kengo Yoshii 3 and Tomoki Todo 4 1 Department of Surgery, Kansai Medical University, Hirakata, Osaka, Japan 2 Research Organization of Science and Technology, Ritsumeikan University, Kusatsu, Shiga, Japan 3 Department of Mathematics and Statistics in Medical Sciences, Kyoto Prefectural University of Medicine, Kyoto, Japan 4 Division of Innovative Cancer Therapy, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan Correspondence to: Masaki Kaibori, email: kaibori@hirakata.kmu.ac.jp Keywords: oncolytic virus; herpes simplex virus; neuroendocrine tumor; mouse xenograft model Received: August 22, 2019     Accepted: December 02, 2019     Published: December 24, 2019 ABSTRACT BACKGROUND: Few chemotherapies are available for neuroendocrine tumors, especially for highly malignant neuroendocrine cancers. The third-generation oncolytic herpes simplex virus type 1 (HSV-1) T-01 selectively replicates in tumor cells and shows cytotoxicity against tumor cells without damaging surrounding normal tissues. We examined the antitumor effect of T-01 to explore novel treatments for patients with neuroendocrine tumors. METHODS: The cytotoxicity of T-01 was tested in two human and one murine neuroendocrine tumor cell lines in vitro . Mouse models with subcutaneously implanted human neuroendocrine tumor QGP1 cells were used to investigate T-01 efficacy in vivo . RESULTS: T-01 showed cytotoxicity against the three cell lines in vitro . In xenograft models, the growth of tumors derived from QGP1 cells was inhibited by T-01 compared with control group. Although weight loss of mice was observed with tumor growth in the control group, it was suppressed by T-01 administration. The antitumor effects of T-01 were dependent on virus concentration and frequency of administration. CONCLUSIONS: T-01 effectively inhibits tumor cell proliferation in a poorly differentiated NEC mouse model. These results suggest that the third-generation oncolytic HSV-1 may serve as a novel treatment for patients with neuroendocrine tumors.
28
Charles G. Moertel, Larry K. Kvols, Michael J. O’Connell et al. · Cancer · 1991 · 839 citations · Full text
Medicine, Endocrinology, Oncology +16